583 related articles for article (PubMed ID: 22307435)
1. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
Yamada T; Terazaki Y; Sakamoto S; Yoshiyama K; Matsueda S; Komatsu N; Waki K; Yamada A; Kawahara A; Kage M; Sugawara S; Yamashita Y; Sasada T; Takamori S; Itoh K
Int J Oncol; 2015 Jan; 46(1):55-62. PubMed ID: 25310280
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
[TBL] [Abstract][Full Text] [Related]
4. Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer.
Alifano M; Falcoz PE; Seegers V; Roche N; Schussler O; Younes M; Antonacci F; Forgez P; Dechartres A; Massard G; Damotte D; Régnard JF
J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1161-7. PubMed ID: 21872279
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K
Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426
[TBL] [Abstract][Full Text] [Related]
6. Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival.
Hubbard MO; Fu P; Margevicius S; Dowlati A; Linden PA
J Thorac Cardiovasc Surg; 2012 Jun; 143(6):1307-13. PubMed ID: 22361247
[TBL] [Abstract][Full Text] [Related]
7. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
[TBL] [Abstract][Full Text] [Related]
8. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer.
Terazaki Y; Yoshiyama K; Matsueda S; Watanabe N; Kawahara A; Naito Y; Suekane S; Komatsu N; Ioji T; Yamada A; Mine T; Terasaki M; Itoh K; Takamori S; Sasada T
Cancer Sci; 2012 Apr; 103(4):638-44. PubMed ID: 22321067
[TBL] [Abstract][Full Text] [Related]
10. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer].
Shen L; Li ZM; Lu S
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):442-6. PubMed ID: 21875485
[TBL] [Abstract][Full Text] [Related]
12. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
13. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
15. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
16. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy.
Cai XW; Xu LY; Wang L; Hayman JA; Chang AC; Pickens A; Cease KB; Orringer MB; Kong FM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1100-5. PubMed ID: 19540063
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K; Sugawara S; Saijo Y; Maemondo M; Sato A; Takamori S; Harada T; Sasada T; Kakuma T; Kishimoto J; Yamada A; Noguchi M; Itoh K; Nakanishi Y
J Immunol Res; 2016; 2016():1745108. PubMed ID: 27274999
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
19. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in stage III non-small-cell lung cancer.
Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
